As eight of the twelve PPIs identified to enrich the “Pathways in Cancer” molecular signature are ECM glycoproteins, it is thus likely that some of the effects of CRP in the context of tumorigenicity specifically involve ECM–receptor signaling among various cell types between the tumoral and stromal compartments. The gene discussed is CRP; the disease is cancer.